The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD
Authors:
Open Access
- 1 July 2021
- journal article
- research article
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 27 (7) , 961-966
Abstract
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan ...Keywords
This publication has 16 references indexed in Scilit:
- Familial Hypercholesterolemia Among Young Adults With Myocardial InfarctionJACC, 2019
- Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin IntoleranceJournal of the American Heart Association, 2019
- Safety and Efficacy of Bempedoic Acid to Reduce LDL CholesterolNew England Journal of Medicine, 2019
- Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled studyAtherosclerosis, 2018
- Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registryAtherosclerosis, 2017
- Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterizationJournal of Clinical Lipidology, 2016
- 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease RiskJACC, 2016
- Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial HypercholesterolemiaJACC, 2016
- 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart DiseaseJACC, 2012
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010